vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Cambium Networks Corp (CMBM). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $40.3M, roughly 1.1× Cambium Networks Corp). Cambium Networks Corp runs the higher net margin — -17.9% vs -19.9%, a 2.0% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -23.2%). Cambium Networks Corp produced more free cash flow last quarter ($-10.8M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -27.2%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Cambium Networks Corporation is an American manufacturer of wireless telecommunications equipment, including Enterprise WiFi, Network switch, Internet of Things, and fixed wireless broadband and Wi-Fi for enterprises products for Internet access. Publicly traded on the NASDAQ stock exchange, it spun out of Motorola in October 2011.

ABCL vs CMBM — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.1× larger
ABCL
$44.9M
$40.3M
CMBM
Growing faster (revenue YoY)
ABCL
ABCL
+811.5% gap
ABCL
788.4%
-23.2%
CMBM
Higher net margin
CMBM
CMBM
2.0% more per $
CMBM
-17.9%
-19.9%
ABCL
More free cash flow
CMBM
CMBM
$33.8M more FCF
CMBM
$-10.8M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
-27.2%
CMBM

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
ABCL
ABCL
CMBM
CMBM
Revenue
$44.9M
$40.3M
Net Profit
$-8.9M
$-7.2M
Gross Margin
36.6%
Operating Margin
-63.7%
-28.4%
Net Margin
-19.9%
-17.9%
Revenue YoY
788.4%
-23.2%
Net Profit YoY
73.9%
71.0%
EPS (diluted)
$-0.03
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
CMBM
CMBM
Q4 25
$44.9M
Q3 25
$9.0M
Q2 25
$17.1M
Q1 25
$4.2M
Q4 24
$5.0M
$40.3M
Q3 24
$6.5M
$44.7M
Q2 24
$7.3M
$45.2M
Q1 24
$10.0M
$47.1M
Net Profit
ABCL
ABCL
CMBM
CMBM
Q4 25
$-8.9M
Q3 25
$-57.1M
Q2 25
$-34.7M
Q1 25
$-45.6M
Q4 24
$-7.2M
Q3 24
$-51.1M
$-34.5M
Q2 24
$-36.9M
$-14.2M
Q1 24
$-40.6M
$-18.4M
Gross Margin
ABCL
ABCL
CMBM
CMBM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
36.6%
Q3 24
43.6%
Q2 24
32.5%
Q1 24
29.8%
Operating Margin
ABCL
ABCL
CMBM
CMBM
Q4 25
-63.7%
Q3 25
-851.8%
Q2 25
-290.2%
Q1 25
-1479.6%
Q4 24
-28.4%
Q3 24
-1439.4%
-69.6%
Q2 24
-1276.2%
-27.2%
Q1 24
-551.5%
-33.1%
Net Margin
ABCL
ABCL
CMBM
CMBM
Q4 25
-19.9%
Q3 25
-637.8%
Q2 25
-203.3%
Q1 25
-1077.2%
Q4 24
-17.9%
Q3 24
-785.4%
-77.3%
Q2 24
-504.3%
-31.5%
Q1 24
-408.0%
-39.2%
EPS (diluted)
ABCL
ABCL
CMBM
CMBM
Q4 25
$-0.03
Q3 25
$-0.19
Q2 25
$-0.12
Q1 25
$-0.15
Q4 24
$-0.26
Q3 24
$-0.17
$-1.22
Q2 24
$-0.13
$-0.51
Q1 24
$-0.14
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
CMBM
CMBM
Cash + ST InvestmentsLiquidity on hand
$128.5M
Total DebtLower is stronger
$67.6M
Stockholders' EquityBook value
$966.9M
$-3.2M
Total Assets
$1.4B
$173.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
CMBM
CMBM
Q4 25
$128.5M
Q3 25
$83.2M
Q2 25
$92.4M
Q1 25
$159.3M
Q4 24
$156.3M
Q3 24
$126.6M
Q2 24
$148.3M
Q1 24
$123.6M
Total Debt
ABCL
ABCL
CMBM
CMBM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$67.6M
Q3 24
$67.6M
Q2 24
$68.9M
Q1 24
$63.8M
Stockholders' Equity
ABCL
ABCL
CMBM
CMBM
Q4 25
$966.9M
Q3 25
$964.0M
Q2 25
$1.0B
Q1 25
$1.0B
Q4 24
$1.1B
$-3.2M
Q3 24
$1.1B
$1.9M
Q2 24
$1.1B
$34.1M
Q1 24
$1.1B
$45.0M
Total Assets
ABCL
ABCL
CMBM
CMBM
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$1.4B
Q1 25
$1.3B
Q4 24
$1.4B
$173.7M
Q3 24
$1.4B
$194.3M
Q2 24
$1.4B
$221.1M
Q1 24
$1.5B
$219.8M
Debt / Equity
ABCL
ABCL
CMBM
CMBM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
36.12×
Q2 24
2.02×
Q1 24
1.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
CMBM
CMBM
Operating Cash FlowLast quarter
$-34.7M
$-10.4M
Free Cash FlowOCF − Capex
$-44.6M
$-10.8M
FCF MarginFCF / Revenue
-99.4%
-26.8%
Capex IntensityCapex / Revenue
21.9%
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$-21.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
CMBM
CMBM
Q4 25
$-34.7M
Q3 25
$-52.6M
Q2 25
$-32.4M
Q1 25
$-11.6M
Q4 24
$-108.6M
$-10.4M
Q3 24
$-28.9M
$8.9M
Q2 24
$-30.0M
$2.4M
Q1 24
$-41.7M
$-15.9M
Free Cash Flow
ABCL
ABCL
CMBM
CMBM
Q4 25
$-44.6M
Q3 25
$-61.5M
Q2 25
$-45.8M
Q1 25
$-22.2M
Q4 24
$-187.0M
$-10.8M
Q3 24
$-47.4M
$6.8M
Q2 24
$-50.1M
$87.0K
Q1 24
$-65.8M
$-17.4M
FCF Margin
ABCL
ABCL
CMBM
CMBM
Q4 25
-99.4%
Q3 25
-687.0%
Q2 25
-267.9%
Q1 25
-524.0%
Q4 24
-3702.8%
-26.8%
Q3 24
-728.4%
15.2%
Q2 24
-683.8%
0.2%
Q1 24
-661.5%
-37.0%
Capex Intensity
ABCL
ABCL
CMBM
CMBM
Q4 25
21.9%
Q3 25
99.7%
Q2 25
78.2%
Q1 25
251.1%
Q4 24
1552.7%
1.1%
Q3 24
284.6%
4.8%
Q2 24
274.6%
5.1%
Q1 24
242.5%
3.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

CMBM
CMBM

Enterprise$16.6M41%
Point To Multi Point$16.4M41%
Other$5.8M14%

Related Comparisons